Drug Approvals, Increased R&D and Strong Product Portfolios Driving New Growth - Research Report on Medivation, MannKind,

Drug Approvals, Increased R&D and Strong Product Portfolios Driving New Growth
 - Research Report on Medivation, MannKind, Questcor Pharmaceuticals, Charles
               River Laboratories and Peregrine Pharmaceuticals

PR Newswire

NEW YORK, March 12, 2013

NEW YORK, March 12, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting
Medivation, Inc. (NASDAQ: MDVN), MannKind Corp. (NASDAQ: MNKD), Questcor
Pharmaceuticals, Inc. (NASDAQ: QCOR), Charles River Laboratories
International, Inc. (NYSE: CRL) and Peregrine Pharmaceuticals, Inc. (NASDAQ:
PPHM). Today's readers may access these reports free of charge - including
full price targets, industry analysis and analyst ratings - via the links
below.

Medivation, Inc. Research Report

After the approval of XTANDI, a capsule treatment for patients with metastatic
castration resistant prostate cancer, analysts already expected that it will
boost Medivation's revenues for fourth quarter and year-end earnings for 2012.
Medivation is pursuing the commercialization of XTANDI where medical need
remains high. XTANDI has a lot of room growth as Medivation continues to
penetrate new markets. The initial sales of XTANDI reached $71.5 million for
full-year 2012. The Full Research Report on Medivation, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/67e4_MDVN]

--

MannKind Corp. Research Report

The growth potential of MannKind is a bullish story for analysts and investors
as it offers therapeutic products for patients with diabetes and cancer. The
markets for the treatment of these illnesses are among the biggest, and this
serves as a market advantage for MannKind. The company reported at 25.2%
increase in research and development as part of its commitment to develop and
to commercialize breakthrough products. MannKind spent $25.3 million during
the fourth quarter for clinical trial related activities. The Full Research
Report on MannKind Corp. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/f4b0_MNKD]

--

Questcor Pharmaceuticals, Inc. Research Report

Questcor's plan to acquire BioVectra Inc. is a step forward to stronger
earnings as it is considered accretive to its financial results. As early as
now, investors are expecting a better performance from Questcor after the
company reported its fourth quarter and full-year 2012 earnings. Questcor's
plan to ramp up its research and development serves as one of the best signals
that have been causing steady inflows. The company's projects underway are for
the treatment of lupus, idiopathic membranous nephropathy, diabetic
nephropathy and amyotrophic lateral sclerosis (ALS). The Full Research Report
on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/21da_QCOR]

--

Charles River Laboratories International, Inc. Research Report

Since Charles River Laboratories acquired Accugenix, Inc. and majority
ownership of Vital River, the company has been seeing a stock uptrend as a
result of increased investments. Charles River Laboratories has been
consistently finding ways to diversify its portfolio while it creates
strategic partnership with other biotechnology players. The decision of
AstraZeneca to partner with Charles River Laboratories is focused on
outsourced regulated safety assessment and development drug metabolism and
pharmacokinetics (DMPK). Recently, the company also announced that its
instrumented colony for cerebrospinal dosing or CSF collection is already
available. The Full Research Report on Charles River Laboratories
International, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/679a_CRL]

--

Peregrine Pharmaceuticals, Inc. Research Report

As a leader in first-in-class monoclonal antibodies focused on the treatment
and diagnosis of cancer, Peregrine Pharmaceuticals has been pursuing multiple
clinical programs with lead product candidates bavituximab and Cotara.
Peregrine Pharmaceutical's bavituximab is set to enter Phase III development
after its 60% improvement in median overall survival in patients. Analysts are
expecting the company to ramp up its research and development amid the
optimism for its ongoing programs. Peregrine Pharmaceuticals is set to report
its third quarter fiscal year 2013 financial results after market close on
March 12, 2013. The Full Research Report on Peregrine Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/e4fd_PPHM]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@investors-alliance.com
Main: +1-(480)-745-7826

SOURCE Investors-Alliance